Cover Image
市場調查報告書

Tykerb (HER2陽性乳癌治療藥): 開發平台分析及市場預測

Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 237586
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
Back to Top
Tykerb (HER2陽性乳癌治療藥): 開發平台分析及市場預測 Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023
出版日期: 2014年09月30日 內容資訊: 英文 55 Pages
簡介

HER2陽性乳癌是全球第2大女性癌症,在初期階段發現的話5年存活率幾乎為100%,不過,後期階段發現的話存活率急速降低。HER2陽性細胞具攻擊性,比傳統HER2陰性類型全存活率低。其中,1998年Herceptin (Trastuzumab)的HER2標靶治療為治療帶來革命,使全存活率也接近了陰性類型。還有以HER2為直接標的之治療方法創造出大市場。以Tykerb為首,透過組合各種化療,延長陽性患者的壽命。 今後,美國、歐盟五國、日本、中國由於老年人口的增加,預計HER2陽性型市場也將成長。

本報告提供HER2陽性乳癌治療藥的治療藥物Tykerb調查分析、疾病概要和治療指南、競爭情形、產品資訊、銷售額預測等彙整資料。

第1章 目錄

第2章 簡介

  • 分析的背景
  • 相關報告
  • 近期預定出版的相關報告

第3章 疾病概要

  • 病因論及病理學
  • 病因論
  • 病理學
  • 基本乳房的生物組織
  • 乳癌 病期分類
  • 預後診斷
  • 生活品質(QOL)
  • 症狀

第4章 疾病管理

  • 治療概要
    • 乳癌 (階段0∼IB)
    • 局部進行性及局部 乳癌 (階段IB∼IIIA)
    • 轉移性 HER2-陽性 乳癌 (階段IV)

第5章 競爭評估

  • 概要

第6章 Tykerb (lapatinib)

  • 概要
  • 有效性
  • 安全性
  • 預測

第7章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC466DFR

GlobalData has released its new PharmaPoint Drug Evaluation report, "Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023". HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third, and fourth-line metastatic.

GSK's Tykerb (lapatinib ditosylate monohydrate) is a small-molecule inhibitor of the intracellular tyrosine kinase domain of EGFR and HER2. Tykerb was approved by the FDA in 2007, and by the European Medicines Agency (EMA) in 2008, for use in locally-advanced or metastatic breast cancer, in combination with Xeloda (capecitabine). In 2010, the FDA and EMA approved Tykerb for use in HR positive locally advanced or metastatic breast cancer in combination with letrozole.

Scope

  • Overview of HER2-Positive Breast Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Tykerb including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Tykerb for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for HER2-Positive Breast Cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Tykerb performance
  • Obtain sales forecast for Tykerb from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Basic Breast Anatomy
  • 3.3. Breast Cancer Staging
  • 3.4. Prognosis
  • 3.5. Quality of Life
  • 3.6. Symptoms

4. Disease Management

  • 4.1. Treatment Overview
    • 4.1.1. Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB)
    • 4.1.2. Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIA)
    • 4.1.3. Treatment of Metastatic HER2-Positive Breast Cancer (Stage IV)

5. Competitive Assessment

  • 5.1. Overview

6. Tykerb (lapatinib)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety

6.4. SWOT Analysis

  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed HER2-Positive Breast Cancer Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
  • 7.5. Primary Research - KOLs Interviewed for this Report
  • 7.6. Primary Research - Prescriber Survey
  • 7.7. About the Authors
    • 7.7.1. Analyst
    • 7.7.2. Therapy Area Director
    • 7.7.3. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: AJCC Stage Definitions for Breast Cancer
  • Table 2: Prognosis for Breast Cancer in the US
  • Table 3: Treatment Guidelines for HER2-Positive Breast Cancer
  • Table 4: Product Profile - Tykerb
  • Table 5: Tykerb SWOT Analysis, 2013
  • Table 6: Global Sales Forecast ($m) for Tykerb, 2013-2023
  • Table 7: HER2-Positive Breast Cancer Incidence, 2013-2023
  • Table 8: Average Body Weight and Surface Area Across the 8MM
  • Table 9: Average Annual Cost of Therapy ($) - Tykerb, First Line
  • Table 10: Physicians Surveyed by Country

List of Figures

  • Figure 1: Basic Breast Anatomy, Including Key Lymph Nodes
  • Figure 2: Primary Completion Dates of Active Phase III Clinical Trials for Tykerb
Back to Top